Literature DB >> 27449145

Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements.

Federico Martinón-Torres1.   

Abstract

Invasive meningococcal disease remains a substantial global public health burden despite being vaccine-preventable worldwide. More than one million cases are reported annually, with average fatality rates ranging from 10% to 40% depending on clinical presentation and geographic location. Survivors may suffer debilitating sequelae that reduce the quality of life for the patient and family members responsible for their care. Major financial burdens are associated with acute treatment and follow-up care, and outbreak management often places extensive financial strains on public health resources. Although the clinical and financial aspects of meningococcal disease burden are straightforward to quantify, other burdens such as lifelong cognitive deficits, psychological stress, adaptive measures for reintegration into society, familial impact, and legal costs are systematically overlooked. These and other facets of disease burden are therefore not systematically considered in cost-effectiveness analyses that public health authorities take into consideration when making decisions regarding vaccination programs. Changing the approach for measuring meningococcal disease burden is necessary to accurately understand the societal consequences of this devastating illness. In this article, the conventional and under-recognized burdens of meningococcal disease are presented and discussed.
Copyright © 2016 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disease burden; Meningococcal disease; Societal consequences

Mesh:

Substances:

Year:  2016        PMID: 27449145     DOI: 10.1016/j.jadohealth.2016.03.041

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   5.012


  23 in total

1.  Costs of Invasive Meningococcal Disease: A Global Systematic Review.

Authors:  Bing Wang; Renee Santoreneos; Hossein Afzali; Lynne Giles; Helen Marshall
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

2.  Cost calculator for mass vaccination response to a US college campus outbreak of serogroup B meningococcal disease.

Authors:  Elizabeth M La; Sandra E Talbird; Koren V Kanadanian; Liping Huang; Joel Fain; Amit Srivastava
Journal:  Hum Vaccin Immunother       Date:  2019-01-16       Impact factor: 3.452

Review 3.  Meningococcal disease and vaccination in college students.

Authors:  Sarah Schaffer DeRoo; Rachel G Torres; Linda Y Fu
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 4.526

4.  Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines.

Authors:  Lidia Serra; Markus Knuf; Federico Martinón-Torres; Kevin Yi; Jamie Findlow
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

5.  Societal costs due to meningococcal disease: a national registry-based study.

Authors:  Nina Gustafsson; Sandra Elkjær Stallknecht; Mette Skovdal; Peter Bo Poulsen; Lars Østergaard
Journal:  Clinicoecon Outcomes Res       Date:  2018-10-02

6.  Factors Associated With Receipt of Meningococcal B Vaccine Among United States Adolescents, National Immunization Survey-Teen, 2017-2018.

Authors:  Caitlin E Hansen; Linda M Niccolai
Journal:  J Adolesc Health       Date:  2021-06-17       Impact factor: 5.012

7.  Natural resistance to Meningococcal Disease related to CFH loci: Meta-analysis of genome-wide association studies.

Authors:  Federico Martinón-Torres; Eileen Png; Chiea Chuen Khor; Sonia Davila; Victoria J Wright; Kar Seng Sim; Ana Vega; Laura Fachal; David Inwald; Simon Nadel; Enitan D Carrol; Nazareth Martinón-Torres; Sonia Marcos Alonso; Angel Carracedo; Elvira Morteruel; Julio López-Bayón; Andrés Concha Torre; Cristina Calvo Monge; Pilar Azcón González de Aguilar; Elisabeth Esteban Torné; María Del Carmen Martínez-Padilla; José María Martinón-Sánchez; Michael Levin; Martin L Hibberd; Antonio Salas
Journal:  Sci Rep       Date:  2016-11-02       Impact factor: 4.996

8.  Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study.

Authors:  Nan-Chang Chiu; Li-Min Huang; Arnold Willemsen; Chiranjiwi Bhusal; Ashwani Kumar Arora; Zenaida Reynoso Mojares; Daniela Toneatto
Journal:  Hum Vaccin Immunother       Date:  2018-02-15       Impact factor: 3.452

9.  The Bexsero Neisseria meningitidis serogroup B vaccine antigen NHBA is a high-affinity chondroitin sulfate binding protein.

Authors:  Tsitsi D Mubaiwa; Lauren E Hartley-Tassell; Evgeny A Semchenko; Christopher J Day; Michael P Jennings; Kate L Seib
Journal:  Sci Rep       Date:  2018-04-25       Impact factor: 4.379

10.  Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits.

Authors:  Andrew Stawasz; Liping Huang; Paige Kirby; David Bloom
Journal:  Front Public Health       Date:  2020-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.